
 <b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/921,819	
	<b>Filing Date</b>	August 3, 2001	
	<b>First Named Inventor</b>	Roland Buelow	
	<b>Group/Art Unit</b>	1632	
	<b>Examiner Name</b>	Anne Marie Sabrina Wehbe	
<b>Total Number of Pages in This Submission</b>	139 pgs.	<b>Attorney Docket Number</b>	39691-0005A


**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Version with Markings Showing Changes <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): stamped return postcard; PTO Form 1449; copies of 5 cited reference
<b>Remarks</b>  <b>AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER.</b>		

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

<b>Firm or Individual name</b>	Ginger R. Dreger, Reg. No. 33,055 HELLER EHRMAN WHITE & McAULIFFE LLP		
<b>Signature</b>			
<b>Date</b>	July 15, 2004	<b>Customer Number:</b>	25213

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail on the date indicated below and addressed to: Mail Stop: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450			
<b>Typed or printed name</b>	Sandra Puljic		
<b>Signature</b>		<b>Date</b>	July 15, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: July 15, 2004

Express Mail Label **EL 993 691 708 US**

Typed or printed name Sandra Puljic

Signature

*Sandra Puljic*

Date

*7-15-04*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Roland Buelow, et al. Docket No.: 39691-0005A  
Serial No.: 09/921,819 Group Art Unit: 1632  
Filing Date: August 3, 2001 Examiner: Anne Marie Sabrina Wehbe  
For: **PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS**

**SUPPLEMENTAL INFORMATION DISCLOSURE**  
**STATEMENT UNDER 37 C.F.R. §1.97 - §1.98**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

The documents submitted with the present Supplemental Information Disclosure Statement were originally submitted on March 17, 2003, but were not considered since they are not in English language and applicants did not provide a concise explanation of their relevance. The present submission serves to rectify this deficiency.

07/21/2004 AWONDAF1 00000050 081641 09921819

01 FC:1806 180.00 DA

**WO 97/18703** is now accompanied by the English translation of its claims. As attested by the claims, this PCT publication concerns a method for constructing transgenic animals by infecting an egg from which the membrane has been eliminated, with a recombinant adenovirus carrying a foreign gene, and transplanting the embryo developed from the egg into the uterus of a host. According to claim 2, the foreign gene can, for example, encode an antibody sequence. The document additionally discloses transgenic animals constructed by the process discussed.

**Japanese Laid-Open Patent Application Publication (Kokai) H6-16698** concerns a method for separation of an antigen-specific antibody from a polyclonal antibody that contains an antigen-nonspecific antibody by column chromatography, using hydroxyapatite as a carrier. The English translation of the claim is enclosed.

**Japanese Patent No. JP11503015** corresponds to PCT Publication No. 96/30498, which is of record. Therefore, a concise explanation of its relevance is apparent from that PCT application.

**WO 96/06160** is accompanied by its English-language equivalents: EP 779,359 and US 6,180,400, therefore, a further explanation of its relevance should not be necessary.

**DE 40 00 939** concerns a method for the preparation of antibodies. The English-language Canadian counterpart of the German patent application is enclosed, which explains its relevance.


Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39691-0005A).

Respectfully submitted,

Dated: July 15, 2004

By:   
Ginger R. Dreger  
Reg. No. 33,055


**HELLER EHRMAN WHITE & MCAULIFFE LLP**

**Customer No. 25213**

275 Middlefield Road

Menlo Park, CA 94025-3506

Telephone: (650) 324-7000/Facsimile: (650) 324-0638



<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>			<b>ATTY. DOCKET NO.:</b> 39691-0005A		<b>SERIAL NO.:</b> 09/921,819		
			<b>APPLICANT :</b> Roland Buelow, et al.				
			<b>FILING DATE:</b> August 3, 2001		<b>GROUP:</b> 1632		
<b>U.S. PATENT DOCUMENTS</b>							
<b>EXAMINER'S INITIALS</b>	<b>PATENT NO.</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE</b>	
	6,180,400 B1	1/30/2001	Kuwana, et al.	435	325		
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>EXAMINER'S INITIALS</b>	<b>PATENT NO.</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION</b>	
						<b>YES</b>	<b>NO</b>
	WO 97/18,703	5/29/1997	PCT	A01K	67/027	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	H6-16698	6/25/1994	JAPAN	C07K	15/14	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	WO 96/30498	10/3/1996	PCT	C12N	5/00	<input type="checkbox"/>	<input type="checkbox"/>
	2,034,034	7/16/1991	CANADA	C12P	021/00	<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.